HMNC Brain Health and Spruce Biosciences have announced the dosing of the first patient in the Phase 2 clinical trial TAMARIND for Major Depressive Disorder (MDD). This trial aims to evaluate tildacerfont, a CRF1 receptor antagonist, as a potential treatment for MDD in patients selected using HMNC’s proprietary patient selection tool.
By targeting a specific subtype of MDD patients with HPA axis dysregulation, TAMARIND seeks to address the underlying biological roots of depression. The collaboration between HMNC and Spruce represents a significant advancement in precision psychiatry, offering personalized solutions to patients with MDD. With anticipated topline results in the first half of 2026, this innovative approach holds promise for revolutionizing the treatment landscape for depression.
Read more from manilatimes.net